ArticleBMC infectious diseases2016
A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa.
Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Prevalence of Hepatitis B Virus Infection in Cameroon: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Antibodies as biomarkers for cancer risk: a systematic review.Clinical and experimental immunology · 2022Pooled it
- Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis.Journal of the Chinese Medical Association : JCMA · 2022Pooled it
- Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review.BMC cancer · 2021Pooled it
- Seroprevalence of hepatitis C virus infection in Cameroon: a systematic review and meta-analysis.BMJ open · 2017Pooled it
- High prevalence of hepatitis delta virus in Cameroon.Scientific reports · 2018Trial
- Primary liver cancer at tertiary healthcare facility in Guinea: a cross-sectional study.BMC gastroenterology · 2026Article
- High Prevalence of Active HDV Infection Among HBsAg-Positive Patients in Urban and Rural Areas in Gabon: A Cross-Sectional Retrospective Study.Health science reports · 2026Article
- Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country survey.JHEP reports : innovation in hepatology · 2025Article
- Prevalence, Molecular Characterization, and Immune Status Response of Hepatitis B Virus Among Healthcare Workers in Yaoundé General Hospital, Cameroon, During May to June 2024: A Hospital-Based Cross-Sectional Study.Health science reports · 2025Article
- Hepatitis Delta Virus and Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Malignancy and viral infections in Sub-Saharan Africa: A review.Frontiers in virology (Lausanne, Switzerland) · 2023Article
- Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection.Journal of hepatocellular carcinoma · 2023Review
- Risk stratification of primary liver cancer.World journal of clinical cases · 2022Article
- Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.World journal of gastroenterology · 2022Review
- Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation.Hepatology international · 2020Article
- Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.Current HIV/AIDS reports · 2020Review
- The oncogenic role of hepatitis delta virus in hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2019Review
- Hepatitis delta virus and hepatocellular carcinoma: an update.Epidemiology and infection · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular Carcinoma (HCC) is one of the commonest cancers in Central Africa, a region with the unusual peculiarity to be hyperendemic for infections with Hepatitis B, C and D viruses. However, data estimating the respective proportions of HCC cases attributable to these viruses are still limited in this area. The current study was undertaken to determine the role of these viruses in HCC compared to non-HCC Cameroonian patients.
methodsA case-control study was conducted in the Gastroenterology Unit of Central Hospital of Yaounde in collaboration with Centre Pasteur of Cameroon. Blood samples of all HCC cases (n = 88) and matched control individuals without known liver disease (n = 85) were tested for serological markers of Hepatitis B, C and D viral infections using commercially available enzyme immune-assay kits. Hepatitis B and C viral loads were quantified for positive patients by real-time PCR using commercial kits.
resultsThe mean age was 46.0 ± 18 and 42.1 ± 16 years old for HCC-patients and controls, respectively for a 2.3 Male/Female sex ratio. The prevalence of hepatitis B surface antigen, antibody to HCV and antibody to HDV were significantly higher in HCC patients (65.90, 20.26 and 26 % respectively) than in control patients (9.23, 4.62 and 1 %) (P < 2.5 10
conclusionHBV and HCV infections are the mains factors of HCC development in Cameroon. Our results show that patients co-infected with HDV are at very high risk to develop HCC. An active surveillance program of patients and, foremost, an easier access to antivirals and primary prevention measures are crucial steps to reduce the incidence of HCC in this country. Due to the lack of truly efficient antiviral therapy, the fate of HDV-infected patients remains, however, particularly worrying.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.